Acute parvovirus B19 infection can present with inflammatory musculoskeletal symptoms that resemble early chronic inflammatory rheumatic disease, potentially complicating diagnosis and treatment decisions. A recent multicentre observational study published in Rheumatology (Oxford)Â found that most adults with acute parvovirus B19-associated inflammatory musculoskeletal disease achieved clinical remission without escalation of disease-modifying antirheumatic drug (DMARD) therapy. The findings highlight the importance of considering acute viral infection in adults presenting with new-onset inflammatory joint symptoms.
Human parvovirus B19 is a non-enveloped, single-stranded DNA virus transmitted primarily through respiratory secretions. Although infection is frequently mild or asymptomatic, adults may develop arthralgia, arthritis, and other systemic manifestations. The musculoskeletal presentation can resemble rheumatoid arthritis or other inflammatory rheumatic diseases, with symptoms ranging from transient joint pain to clinically apparent polyarthritis. Parvovirus B19 can also cause transient aplastic crises, particularly in individuals with underlying haematological disorders, and persistent infection-related anaemia in immunocompromised patients.
The non-interventional, multicentre observational study conducted across rheumatology units within the Gruppo Italiano di Ricerca Clinica in Reumatologia (GIRRCS) network evaluated the clinical presentation, selected imaging findings, and remission trajectories of adults with acute parvovirus B19-associated inflammatory musculoskeletal disease. Eligible patients had new-onset inflammatory musculoskeletal manifestations, positive anti-parvovirus B19 immunoglobulin M (IgM), and symptom onset within four weeks. The primary outcome was the time from symptom onset to the first rheumatologist-confirmed assessment documenting resolution of inflammatory musculoskeletal manifestations. Patients requiring escalation of DMARD therapy were analysed separately.
A total of 24 adults were enrolled, of whom 18 (75.0%) were women. The mean age was 44.4 ± 14.8 years. Polyarticular involvement was observed in 14 patients (58.3%), while 10 (41.7%) had oligoarticular involvement. Enthesitis was reported in four patients (16.7%), and no cases of dactylitis were recorded. Inflammatory markers were modestly elevated, while most patients with complete autoantibody data were seronegative. Imaging was performed selectively according to clinical indications, and inflammatory abnormalities were documented in the examinations performed.
Follow-up data were available for 21 patients. Of these, 20 (95.2%) achieved clinical remission without DMARD escalation. The median time to documented remission was 21 days, with an interquartile range of 10–60 days and an overall range of 7–135 days. One patient required biologic therapy escalation because of persistent inflammatory disease. Exploratory regression analyses did not identify robust associations between the assessed variables and the timing of documented remission.
The findings indicate that acute parvovirus B19-associated musculoskeletal disease can resemble early inflammatory rheumatic disease, although the clinical course and time to remission vary between patients. The high proportion of patients achieving remission without treatment escalation supports careful clinical assessment and follow-up before attributing new-onset inflammatory symptoms to a chronic rheumatic condition or escalating immunosuppressive treatment.
However, the findings should be interpreted cautiously because of the small sample size, referral-based study population, selective use of imaging, and reliance on IgM serology for identifying acute infection. A positive anti-parvovirus B19 IgM result should be interpreted in the context of the clinical presentation and other relevant investigations. Larger prospective studies are needed to clarify predictors of persistent disease and establish the optimal diagnostic and follow-up approach.
Reference
Ruscitti P, Costa L, Mastrangelo A, Viapiano F, Tasso M, Sgarlata G, et al. Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS network. Rheumatology (Oxford). 2026;65(9):keag456.